TSE:PLI

ProMetic Life Sciences Competitors

Add
Compare
Today's Range N/A
50-Day Range
C$13.54
MA: C$13.60
C$13.60
52-Week Range N/A
Volume921 shs
Average Volume8,002 shs
Market CapitalizationC$315.66 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

ProMetic Life Sciences (TSE:PLI) Vs. CXR, APS, BU, BLU, TH, and NRI

Should you be buying PLI stock or one of its competitors? Companies in the industry of "biotechnology" are considered alternatives and competitors to ProMetic Life Sciences, including Concordia International (CXR), Aptose Biosciences (APS), Burcon NutraScience (BU), BELLUS Health (BLU), Theratechnologies (TH), and Nuvo Pharmaceuticals Inc. (NRI.TO) (NRI).

ProMetic Life Sciences (TSE:PLI) and Concordia International (TSE:CXR) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, earnings, profitability, institutional ownership, valuation and risk.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for ProMetic Life Sciences and Concordia International, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ProMetic Life Sciences0000N/A
Concordia International0000N/A

Profitability

This table compares ProMetic Life Sciences and Concordia International's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ProMetic Life SciencesN/AN/AN/A
Concordia InternationalN/AN/AN/A

Earnings & Valuation

This table compares ProMetic Life Sciences and Concordia International's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ProMetic Life SciencesC$39.91 million0.00C$-1,470,117,780.00C($63.06)N/A
Concordia InternationalC$569.62 million0.00C$17.20 billionC$351.68N/A

Concordia International has higher revenue and earnings than ProMetic Life Sciences.

Summary

Concordia International beats ProMetic Life Sciences on 4 of the 4 factors compared between the two stocks.

Aptose Biosciences (TSE:APS) and ProMetic Life Sciences (TSE:PLI) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, earnings, analyst recommendations, dividends, risk, institutional ownership and valuation.

Valuation & Earnings

This table compares Aptose Biosciences and ProMetic Life Sciences' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aptose BiosciencesN/AN/AN/AC($0.85)-7.67
ProMetic Life SciencesC$39.91 million0.00C$-1,470,117,780.00C($63.06)N/A

Aptose Biosciences has higher earnings, but lower revenue than ProMetic Life Sciences. Aptose Biosciences is trading at a lower price-to-earnings ratio than ProMetic Life Sciences, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Aptose Biosciences and ProMetic Life Sciences, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Aptose Biosciences00203.00
ProMetic Life Sciences0000N/A

Aptose Biosciences currently has a consensus price target of C$12.00, suggesting a potential upside of 84.90%.

Profitability

This table compares Aptose Biosciences and ProMetic Life Sciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Aptose BiosciencesN/AN/AN/A
ProMetic Life SciencesN/AN/AN/A

Burcon NutraScience (TSE:BU) and ProMetic Life Sciences (TSE:PLI) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, earnings, analyst recommendations, valuation, dividends, risk and profitability.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Burcon NutraScience and ProMetic Life Sciences, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Burcon NutraScience00103.00
ProMetic Life Sciences0000N/A

Burcon NutraScience presently has a consensus target price of C$5.00, indicating a potential upside of 3.31%.

Profitability

This table compares Burcon NutraScience and ProMetic Life Sciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Burcon NutraScienceN/AN/AN/A
ProMetic Life SciencesN/AN/AN/A

Earnings and Valuation

This table compares Burcon NutraScience and ProMetic Life Sciences' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Burcon NutraScienceC$12,045.0043,036.02C$107,101.00C$0.004,840.00
ProMetic Life SciencesC$39.91 million0.00C$-1,470,117,780.00C($63.06)N/A

Burcon NutraScience has higher earnings, but lower revenue than ProMetic Life Sciences. ProMetic Life Sciences is trading at a lower price-to-earnings ratio than Burcon NutraScience, indicating that it is currently the more affordable of the two stocks.

Summary

Burcon NutraScience beats ProMetic Life Sciences on 4 of the 5 factors compared between the two stocks.

ProMetic Life Sciences (TSE:PLI) and BELLUS Health (TSE:BLU) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, profitability, dividends, analyst recommendations, risk, earnings and institutional ownership.

Profitability

This table compares ProMetic Life Sciences and BELLUS Health's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ProMetic Life SciencesN/AN/AN/A
BELLUS HealthN/AN/AN/A

Analyst Ratings

This is a breakdown of current ratings for ProMetic Life Sciences and BELLUS Health, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ProMetic Life Sciences0000N/A
BELLUS Health01202.67

Valuation & Earnings

This table compares ProMetic Life Sciences and BELLUS Health's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ProMetic Life SciencesC$39.91 million0.00C$-1,470,117,780.00C($63.06)N/A
BELLUS HealthC$15,000.0029,559.16C$-42,145,306.00C($0.54)-10.52

BELLUS Health has lower revenue, but higher earnings than ProMetic Life Sciences. BELLUS Health is trading at a lower price-to-earnings ratio than ProMetic Life Sciences, indicating that it is currently the more affordable of the two stocks.

Summary

BELLUS Health beats ProMetic Life Sciences on 3 of the 5 factors compared between the two stocks.

ProMetic Life Sciences (TSE:PLI) and Theratechnologies (TSE:TH) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, analyst recommendations, dividends, risk, valuation, earnings and institutional ownership.

Earnings and Valuation

This table compares ProMetic Life Sciences and Theratechnologies' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ProMetic Life SciencesC$39.91 million0.00C$-1,470,117,780.00C($63.06)N/A
TheratechnologiesC$66.05 million6.48C$-34,627,329.00C($0.37)-12.36

Theratechnologies has higher revenue and earnings than ProMetic Life Sciences. Theratechnologies is trading at a lower price-to-earnings ratio than ProMetic Life Sciences, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares ProMetic Life Sciences and Theratechnologies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ProMetic Life SciencesN/AN/AN/A
TheratechnologiesN/AN/AN/A

Analyst Recommendations

This is a summary of current recommendations and price targets for ProMetic Life Sciences and Theratechnologies, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ProMetic Life Sciences0000N/A
Theratechnologies02002.00

Theratechnologies has a consensus price target of C$3.75, indicating a potential downside of 17.76%.

Summary

Theratechnologies beats ProMetic Life Sciences on 3 of the 4 factors compared between the two stocks.

ProMetic Life Sciences (TSE:PLI) and Nuvo Pharmaceuticals Inc. (NRI.TO) (TSE:NRI) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, risk, analyst recommendations, dividends, earnings, profitability and institutional ownership.

Profitability

This table compares ProMetic Life Sciences and Nuvo Pharmaceuticals Inc. (NRI.TO)'s net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ProMetic Life SciencesN/AN/AN/A
Nuvo Pharmaceuticals Inc. (NRI.TO)N/AN/AN/A

Earnings & Valuation

This table compares ProMetic Life Sciences and Nuvo Pharmaceuticals Inc. (NRI.TO)'s revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ProMetic Life SciencesC$39.91 million0.00C$-1,470,117,780.00C($63.06)N/A
Nuvo Pharmaceuticals Inc. (NRI.TO)C$76.09 million5.35C$-6,980,844.00C($0.61)-58.36

Nuvo Pharmaceuticals Inc. (NRI.TO) has higher revenue and earnings than ProMetic Life Sciences. Nuvo Pharmaceuticals Inc. (NRI.TO) is trading at a lower price-to-earnings ratio than ProMetic Life Sciences, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings and target prices for ProMetic Life Sciences and Nuvo Pharmaceuticals Inc. (NRI.TO), as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ProMetic Life Sciences0000N/A
Nuvo Pharmaceuticals Inc. (NRI.TO)00103.00

Summary

Nuvo Pharmaceuticals Inc. (NRI.TO) beats ProMetic Life Sciences on 4 of the 5 factors compared between the two stocks.


ProMetic Life Sciences Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Concordia International logo
CXR
Concordia International
0.7N/AN/AC$1.22 billionC$569.62 million0.07High Trading Volume
APS
Aptose Biosciences
1.3$6.49flatC$576.86 millionN/A-7.67
BU
Burcon NutraScience
1.2$4.84flatC$518.37 millionC$12,045.004,840.00News Coverage
Gap Down
BLU
BELLUS Health
0.5$5.66flatC$443.39 millionC$15,000.00-10.52Gap Up
Theratechnologies logo
TH
Theratechnologies
0.7$4.56flatC$427.92 millionC$66.05 million-12.36News Coverage
Gap Up
NRI
Nuvo Pharmaceuticals Inc. (NRI.TO)
0.8$35.78flatC$407.41 millionC$76.09 million-58.36
MDNA
Medicenna Therapeutics
0.5$5.07flatC$268.21 millionN/A-16.41News Coverage
NEPT
Neptune Wellness Solutions
1.2$1.56flatC$258.17 millionC$52.78 million-1.16
EMC
Emblem
0.5$1.88flat$248.31 million$5.71 million-9.89
IMV logo
IMV
IMV
1.2$3.49flatC$236.31 millionC$3,000.00-6.04Gap Down
ATE
Antibe Therapeutics
1.3$4.58flatC$208.42 millionC$9.33 million-5.82
ONC
Oncolytics Biotech
1.2$3.86flatC$203.69 millionN/A-6.89Analyst Report
RVX
Resverlogix
0.7$0.87flatC$203.57 millionN/A79.09Upcoming Earnings
Gap Down
FRX
Fennec Pharmaceuticals
0.5$7.51flatC$195.28 millionC$170,000.00-7.84
HBP
Helix BioPharma
0.5$0.88flatC$124.20 millionN/A-16.00Gap Down
IPA
ImmunoPrecise Antibodies
0.4$13.58flatC$123.03 millionC$17.18 million-63.46
ACST
Acasti Pharma Inc. (ACST.V)
0.8$0.59flatC$88.79 millionC$81,000.0017.35Gap Up
NVH
Novoheart
0.5$0.53flatC$79.23 millionC$423,500.00-13.95
PDP
Pediapharm
0.5$0.30flatC$66.36 millionC$11.16 million-4.11
MBX
Microbix Biosystems
0.9$0.60flatC$65.67 millionC$11.64 million-11.76Gap Down
SBM
Sirona Biochem
0.5$0.35flatC$58.80 millionC$123,870.00-26.92
PMN
ProMIS Neurosciences
0.5$0.17flatC$52.01 millionC$1,787.00-8.50Gap Up
COV
Covalon Technologies
0.6$1.43flatC$37.44 millionC$23.84 million-6.01Gap Up
Emerald Health Therapeutics logo
EMH
Emerald Health Therapeutics
0.5$0.27flatC$34.02 millionC$13.02 million-0.39
IGX
IntelGenx Technologies
0.9$0.60flatC$30.87 millionC$1.54 million-9.23High Trading Volume
QPT
Quest PharmaTech
0.8$0.10flatC$21.76 millionC$38,871.000.15High Trading Volume
Gap Down
CZO
Ceapro
0.7$0.78flatC$21.65 millionC$16.14 million23.64Gap Up
CTX
Crescita Therapeutics
0.6$0.84flatC$17.34 millionC$15.64 million420.00
KNE
Kane Biotech
0.4$0.16flatC$14.12 millionC$1.34 million-4.57Gap Down
GSD
Devonian Health Group
0.5$0.26flatC$13.96 millionC$1.59 million-5.42Gap Up
PAS
Pascal Biosciences
0.6$0.10flatC$12.70 millionN/A-4.32Gap Down
NSP
Naturally Splendid Enterprises
0.6$0.06flatC$11.06 millionC$2.03 million-1.40Gap Up
MPH
Medicure
0.7$1.58flatC$10.80 millionC$12.71 million-1.02
BTI
Bioasis Technologies
0.7$0.39flatC$10.16 millionC$4.12 million35.00
HEM
Hemostemix
0.6$0.45flatC$9.07 millionN/A-2.68Gap Down
ICO
iCo Therapeutics
0.5$0.11flatC$7.69 millionN/A-8.75
IBT
IBEX Technologies
0.7$0.37flatC$6.94 millionC$5.60 million6.76News Coverage
Gap Down
IOT
Innovotech
0.8$0.15flatC$6.52 millionC$1.04 million75.00Gap Up
BCT
BriaCell Therapeutics
0.5$4.00flatC$4.48 millionN/A-1.29High Trading Volume
RVV
Revive Therapeutics
0.5$0.08flatC$3.62 millionN/A-3.64High Trading Volume
Gap Down
COT
Cotinga Pharmaceuticals Inc. (COT.V)
0.5$0.04flatC$1.54 millionN/A-0.30Gap Up
PBS
Pacgen Life Science Co. (PBS.V)
0.6$0.03flatC$1.30 millionC$302,079.00-5.00Gap Down
MFS
Medifocus Inc. (MFS.V)
0.5$0.01flatC$925,000.00C$2.23 million-1.00
CHV
(CHV)
0.5N/AN/A$0.00N/A0.00High Trading Volume
PREV
(PREV)
0.7N/AN/A$0.00N/A0.00High Trading Volume
COM
138267 (COM.TO)
0.5N/AN/AC$0.00N/A0.00
MYM
17031
0.4N/AN/AC$0.00N/A0.00
CURE
Direxion Daily Healthcare Bull 3X Shares
0.5N/AN/A$0.00N/A0.00High Trading Volume
Gap Down
HALO
Halozyme Therapeutics
1.3$45.95flatC$0.00C$267.59 million50.49
LTY
Liberty Biopharma
0.6$2.00flatC$0.00N/A-12.66News Coverage
Gap Down
This page was last updated on 4/15/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.